Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Molecular Devices Introduces EarlyTox Cardiotoxicity Kit

Published: Wednesday, September 18, 2013
Last Updated: Wednesday, September 18, 2013
Bookmark and Share
The EarlyTox™ Cardiotoxicity Kit is a fast, simple and reliable fluorescence-based kit for identifying cardiotoxicity of drug candidates early in the discovery process.

EarlyTox allows researchers to prioritize lead compounds and drug candidates, and direct medicinal chemistry efforts sooner, improving productivity and reducing costs associated with downstream safety testing. The kit may also enable the discovery of new cardiac drug candidates.

The EarlyTox Cardiotoxicity Kit measures changes in cytoplasmic calcium which are associated with cardiomyocyte beating. The kit combines a novel calcium sensitive dye and proprietary masking technology, resulting in the largest dynamic range and enhanced discrimination of beat pattern detail. Unlike other calcium dyes, the new dye formulation minimizes non-specific effects on beat characteristics.

The optimized calcium-sensitive dye formulation binds with calcium ions in the cell cytoplasm, enabling measurement of any changes in calcium concentration. The masking technology remains outside the cell and acts to reduce extracellular background fluorescence. When compared to traditional safety assays, this robust, high throughput assay format measures 384 samples in minutes rather than hours.

Kevin Chance, President of Molecular Devices, commented: “Highly predictive and biologically relevant in vitro assays suitable for high throughput screening are critical to improving efficiencies and reducing the high costs associated with compounds that fail during cardiac safety assessment. When paired with the FLIPR® Tetra System, and other microplate readers from Molecular Devices, the EarlyTox Cardiotoxicity Kit is a powerful tool in eliminating cardiotoxic compounds earlier in the drug discovery process."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecular Devices Partners with Roche
Partnership will develop custom Ruthenium Nano-TRF Detection Platform.
Thursday, November 06, 2014
Molecular Devices Becomes Global Distributor of IonFlux
Molecular Devices makes deal with Fluxion Biosciences to distribute their automated electrophysiology systems and associated products.
Tuesday, May 28, 2013
Molecular Devices Forms Scientific Advisory Board
Multidisciplinary team will guide product and application development to deliver maximum value to customers.
Thursday, December 27, 2012
Molecular Devices to attend ADME & Predictive Toxicology Europe
Company is to showcase its SpectraMax® Paradigm® microplate reader during the European conference in Munich, Germany, 13-14 March 2012.
Wednesday, February 29, 2012
Molecular Devices Awarded Patent for Population Patch Clamp Recording Technique
The parallel recording technique measures ionic currents from a population of cells, rather than single cells, on planar patch clamp systems and enhances ion channel assay success rates to near 100%.
Tuesday, January 10, 2012
Registration opens for RNAi and High Content Imaging 2011
Molecular Devices Inc. announces that they have opened registration for its RNAi & High Content Imaging Symposium 2011, to be held at the Oxford Spires Four Pillars, Oxford on 1st April 2011.
Tuesday, February 08, 2011
Molecular Devices Launches New Products & Customer-Focused Brand at Society for Biomolecular Sciences Meeting
New IonWorks Barracuda™ Automated High-Speed Patch Clamp System & AquaMax® 2000/4000 Microplate Washer 96 Cell-Wash Head
Thursday, April 08, 2010
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!